Translational Pathology Core

项目总结-摘要（转化病理学核心） 转化病理学核心的首要使命是收集与以下疾病相关的人体组织： 临床信息并分发给SPORE研究者，以促进转化研究。平移 病理学核心将在病理学部门内进行保管和管理，以确保 不折不扣的患者护理、有限组织资源的最佳利用以及患者保密性。具体 核心的目标包括：（1）不折不扣的病人护理和正确的外科病理诊断。所有组织 将根据IRB批准的方案收集。(2)有可能获得合适的大脑，乳房， 胰腺和其他未来的组织，这取决于孢子项目的需要。核心将密切合作 与现有的组织和分子病理学共享的组织采购服务， 密歇根大学Rogel癌症中心的资源。托马斯佐丹奴博士一直是这个项目的负责人 自1996年以来，一直保持资源共享。(3)来自外科手术的人体组织的专家病理学审查 病理标本神经病理学家和成功的神经胶质瘤研究者Sriram Venneti博士将审查 所有的脑组织，博士Jiaqi施，胃肠道病理学家与胰腺癌的特殊专长，将审查所有 胰腺组织和托马斯佐丹奴博士，一位在乳腺癌方面有数十年经验的外科病理学家， 病理学，将审查所有乳房组织。根据需要，来自卫生部的其他专家病理学家 将招募病理学人员以支持核心。(4)基于组织的基因表达和生物标志物验证 研究，如免疫组织化学，正如孢子项目的需要所表明的。Dafydd医生 托马斯是一位组织调查专家，他将领导这些工作。总的来说， 转化病理学核心将通过促进转化研究来支持这些项目， 其他NCI支持的网络资源。

PROJECT SUMMARY-ABSTRACT (Translational Pathology Core) The overarching mission of the Translational Pathology Core is to collect human tissues associated with clinical information and distribute to SPORE investigators to facilitate translational research. The Translational Pathology Core will be housed and administered within the Department of Pathology to ensure uncompromised patient care, optimal use of limited tissue resources, and patient confidentiality. The specific goals of the core include: (1) Uncompromised patient care and proper surgical pathology diagnosis. All tissues will be collected under IRB-approved protocols. (2) Prospective procurement of appropriate brain, breast, pancreas and other future tissues as dictated by the needs of the SPORE projects. The core will work closely with and enhance the existing Tissue Procurement Service of the Tissue and Molecular Pathology Shared Resource of the University of Michigan Rogel Cancer Center. Dr. Thomas Giordano has been a director of this shared resource continuously since 1996. (3) Expert pathology review of human tissues from surgical pathology specimens. Dr. Sriram Venneti, a neuropathologist and accomplished glioma investigator, will review all brain tissues, Dr. Jiaqi Shi, a GI pathologist with special expertise in pancreas cancer, will review all pancreas tissues, and Dr. Thomas Giordano, a surgical pathologist with decades of experience in breast pathology, will review all breast tissues. As needed, other expert pathologists from the Department of Pathology will be recruited to support the core. (4) Tissue-based gene expression and biomarker validation studies, such as immunohistochemistry, as indicated by the needs of the SPORE projects. Dr. Dafydd Thomas, an expert in tissue-based investigation, will lead these efforts. Collectively, the services of the Translational Pathology Core will support the projects by facilitating translational research and also enhance the resources of other NCI-supported networks.